The importance of randomized clinical trials and evidence-based medicine: A clinician's perspective
Corresponding Author
Harold L. Kennedy M.D., MPH
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
Cardiovascular Division Department of Medicine University of Minnesota 420 Delaware Street SE Minneapolis, MN 55455, USASearch for more papers by this authorCorresponding Author
Harold L. Kennedy M.D., MPH
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
Cardiovascular Division Department of Medicine University of Minnesota 420 Delaware Street SE Minneapolis, MN 55455, USASearch for more papers by this authorAbstract
Clinical evaluation of therapies for patient care has evolved during the twentieth century from a variety of scientific methods. As a result of medical, political, and economic changes that occurred in the 1990s, randomized clinical trials and evidence-based methods are presently in the forefront of the physician's thinking in the decision-making process for therapeutic interventions. A new standard of patient care has emerged during this process. This report provides a clinician's viewpoint of the importance and interpretation of evidence-based methods and suggests a strategy when such evidence does not exist.
References
- 1 Evidence-Based Medicine Working Group: Evidence-based medicine. A new approach to teaching the practice of medicine. J Am Med Assoc 1992; 268: 2420–2425
- 2 Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNail BAJ: Knowledge and practice of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994; 331: 1136–1142
- 3 Osler WM: The Principles and Practice of Medicine. New York: D. Appleton and Co., 1892
- 4 Lewis T: Diseases of the Heart. London: Macmillan & Co., Ltd, 1933
- 5 Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N: Angina pectoris. 1. A variant form of angina pectoris. Preliminary report. Am J Med 1959; 27: 375–388
- 6 Dressler W: Idiopathic recurrent pericarditis. Am J Med 1955; 18: 591–601
- 7 Sacks H, Chalmers TC, Smith H: Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233–240
- 8 Armitage P: Statistical Methods in Medical Research. New York: Wiley, 1971
- 9 Medical Research Council: Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769–782
- 10
D'Arcy Hart P:
History of randomised control trials.
Lancet
1972;
1:
965
10.1016/S0140-6736(72)91536-X Google Scholar
- 11 Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585–612
- 12 Fleming TR, DeMets DL: Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605–613
- 13 Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA: Blood pressure, stroke and coronary heart disease. 2. Short-term reductions in blood pressure; overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838
- 14 The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023–1038
- 15 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993; 153: 154–183
- 16 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446
- 17 ISIS-I (First International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57–66
- 18 Yusuf S, Collins R, Peto R, Furburg C, Stampfer MJ, Goldhaber SZ, Hennekens CH: Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556–585
- 19 Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–1435
- 20 Kennedy HL, Rosenson RS: Physician use of beta-adrenergic blocking therapy—a changing perspective. J Am Coll Cardiol 1995; 26: 547–552
- 21 Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thilbault G, Goldman L: Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. J Am Med Assoc 1997; 277: 115–121
- 22 Krumholz HM, Vaccarino V, Ellerbeck EF, Kiefe C, Hennen J, Kresowik TF, Gold JA, Jenks SF, Radford MJ: Determinants of appropriate use of angiotensin converting enzyme inhibitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol 1997; 79: 581–586
- 23 Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Hoye I, Pfeffer M: Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 1997; 29: 229–236
- 24 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412
- 25 Hine LK, Gross TP, Kennedy DL: Outpatient antiarrhythmic drug use from 1970 through 1986. Arch Intern Med 1989; 149: 1524–1527
- 26 Lie KI, Wellens HJ, Van Capelle FJ, Durrer D: Lidocaine in the prevention of primary ventricular fibrillation. N Engl J Med 1974; 291: 1324–1326
- 27 Lown B, Wolf M: Approaches to sudden death from coronary artery disease. Circulation 1978; 58: 581–584
- 28 Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Monno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL: Mortality and morbidity in patients receiving encainide, flecainide or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788
- 29 Mirvis DM, Chang CF: Managed care, managing uncertainty. Arch Intern Med 1997; 157: 385–388
- 30 Mayer TR: HMOs: Origins and development. N Engl J Med 1985; 312: 590–594
- 31 Iglehart JK: The American health care system—managed care. N Engl J Med 1992; 327: 742–747
- 32 Agency for Health Care Policy and Research (AHCPR) established December 1989 under Public Law 101–239. Omnibus Budget Reconciliation Act of 1989.
- 33 Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389
- 34 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307
- 35 Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009
- 36 Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, El Kayam CL, Kukin ML: The PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468–1475
- 37 Feldman A, Young J, Bourge R, Carson P, Jaski B, DeMets D, White BG, Cohn JN, for the VEST Investigators: Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VEST) (abstr). J Am Coll Cardiol 1997; 29: 64A
- 38 Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, and the PROFILE Investigators and Coordinators: Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study (abstr). Circulation 1993; 88 (suppl 1): 1–301
- 39 Berg AO, Atkins D, Tierney W: Clinical practice guidelines in practice and education. J Gen Intern Med 1997; 12: S25–S33
- 40 Califf RM, Woodlief LH: Pragmatic and mechanistic trials. Eur Heart J 1997; 18 (3): 367–370
- 41 Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248–254
- 42 Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355
- 43 Pfeffer MA, Stevenson LW: B-adrenergic blockers and survival in heart failure. N Engl J Med 1996; 334: 1396–1397
- 44 Yusuf S: Digoxin in heart failure: Results of the recent digoxin investigation group trial in the context of other treatments for heart failure. Eur Heart J 1997; 18: 1685–1688
- 45 McKelvie R, Yusuf S: Large trials and meta-analyses. In Heart Failure: Scientific Principles and Clinical Practice. (Eds. P Poole-Wilson, W Colucci, K Chatterjee, B Massie, A Coats), p. 1–19. New York: Churchill Livingstone, 1995
- 46 Ware JH, Antman EM: Equivalence trials. N Engl J Med 1997; 337: 1159–1161
- 47 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–2223
- 48 The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators: A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337: 1124–1130
- 49 Bailar JC: The promise and problems of meta-analysis. N Engl J Med 1997; 337: 559–561
- 50 Pogue J, Yusuf S: Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351: 47–52
- 51 Lau J, Ioannidis JPA, Schmid CH: Summing up evidence: One answer is not always enough. Lancet 1998; 351: 123–127
- 52 Oxman A: Preparing and maintaining systematic reviews. In Cochrane Collaboration Handbook., Section VI. Oxford, England: Cochrane Collaboration, 1996
- 53 Begg CB, Berlin JA: Publication bias: A problem in interpreting medical data. J R Statist Soc A 1988; 151: 419–463
- 54 Dickersin K: The existence of publication bias and risk factors for its occurrence. J Am Med Assoc 1990; 263: 1385–1389
- 55 Dickersin K, Min Y-I: Publication bias: The problem that won't go away. Ann N Y Acad Sci 1993; 703: 135–148
- 56 Ioannidis JPA: Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. J Am Med Assoc 1998; 279: 281–286
- 57 Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248–254
- 58 Teo KK, Yusuf S: Role of magnesium in reducing mortality in acute myocardial infarction. Drugs 1993; 46: 347–359
- 59 Yusuf S, Teo K, Woods K: Intravenous magnesium in acute myocardial infarction: An effective, safe, simple and inexpensive intervention. Circulation 1993; 87: 2043–2046
- 60 ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685
- 61 LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between meta-analyses and subsequent large randomized, control trials. N Engl J Med 1997; 337: 536–542
- 62 Ioannidis JPA, Cappelleri JC, Lau J: Meta-analyses and large randomized, controlled trials (letter). N Engl J Med 1998; 338: 59
- 63 Bailar JC: Meta-analyses and large randomized, controlled trials (letter). N Engl J Med 1998; 338: 62
- 64 Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta-blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–371
- 65 Jaillon P: Relevance of intrinsic sympathomimetic activity for beta-blockers. Am J Cardiol 1990; 66: 21C–23C
- 66 Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997; 349: 747–752
- 67 Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC: A comparison of results of meta-analyses of randomized controlled trials and recommendations of clinical experts: Treatments for myocardial infarction. J Am Med Assoc 1992; 268: 240–248
- 68 Pealunik SL, Classen DC, Evans RS, Burke JP: Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med 1996; 124: 884–890
- 69 Ranjadayalan K, Umachandran V, Timmis AD: Clinical impact of introducing thrombolytic and aspirin therapy into the management policy of a coronary care unit. Am J Med 1992; 92: 233–238
- 70 Pozniak A: Surrogacy in HIV-I clinical trials. Lancet 1998; 351: 536–537